RegulatoryNov 5, 2026, 08:41 AM
Baird Medical Receives Nasdaq Minimum Bid Price Deficiency Notice
AI Summary
Baird Medical Investment Holdings Ltd. received a notification from Nasdaq on November 2, 2026, indicating its ordinary shares have fallen below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has 180 days, until May 3, 2027, to regain compliance. While the shares will continue trading uninterrupted under the ticker BDMD, failure to meet the requirement could lead to delisting or an additional grace period. The company is exploring options to address the deficiency and believes its current market valuation does not accurately reflect its business fundamentals.
Key Highlights
- Baird Medical received a Nasdaq notification on November 2, 2026, for failing to meet the minimum bid price requirement ($1.00) for 30 consecutive business days.
- The company has 180 calendar days, until May 3, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days.
- Failure to comply by May 3, 2027, may allow for an additional 180-day grace period if other listing requirements are met.
- The notification does not immediately delist the company's shares, which will continue to trade under the ticker 'BDMD'.
- Baird Medical is exploring options to regain compliance and stated its current market valuation may not reflect its business fundamentals.
Price Impact
More from BDMD